Supplementary Materials

Supplementary Material for:

Lymph node fibroblastic reticular cell transplants show robust therapeutic efficacy in high-mortality murine sepsis

Anne L. Fletcher,* Jessica S. Elman, Jillian Astarita, Ryan Murray, Nima Saeidi, Joshua D'Rozario, Konstantin Knoblich, Flavian D. Brown, Frank A. Schildberg, Janice M. Nieves, Tracy S. P. Heng, Richard L. Boyd, Shannon J. Turley,* Biju Parekkadan*

*Corresponding author. E-mail: biju_parekkadan@hms.harvard.edu (B.P.); turley.shannon@gene.com (S.J.T.); a.fletcher@bham.ac.uk (A.L.F.)

Published 13 August 2014, Sci. Transl. Med. 6, 249ra109 (2014)
DOI: 10.1126/scitranslmed.3009377

This PDF file includes:

  • Fig. S1. Phenotype of ex vivo–expanded FRCs.
  • Fig. S2. FRCs inhibit growth of E. coli in vitro in a NOS2-independent manner.
  • Fig. S3. Flow cytometric analysis of leukocyte subsets in peritoneal lavage fluid after FRC therapy.
  • Fig. S4. Flow cytometric analysis of leukocyte subsets in blood after FRC therapy.
  • Fig. S5. Flow cytometric analysis of leukocyte subsets in spleen after FRC therapy.
  • Fig. S6. Nitrite measurement in serum after FRC therapy.
  • Fig. S7. FRCs do not secrete NO in vitro in response to LPS.
  • Fig. S8. TNFRI does not mediate the survival benefit seen in FRC-treated mice with CLP sepsis.
  • Fig. S9. TNFa production by restimulated peritoneal and splenic leukocytes.
  • Table S1. GenBank accession number for microarray analyses of cultured FRCs.

[Download PDF]